Insulet Dirección

Dirección controles de criterios 2/4

Insulet's El consejero delegado es Jim Hollingshead , nombrado en Jun 2022, tiene un mandato de 1.5 años. la remuneración anual total es $11.18M , compuesta por 3.9% salario y 96.1% primas, incluidas acciones y opciones de la empresa. posee directamente 0.018% de las acciones de la empresa, por valor de €2.33M . La antigüedad media del equipo directivo y del consejo de administración es de 3.6 años y 4.9 años respectivamente.

Información clave

Jim Hollingshead

Chief Executive Officer (CEO)

US$12.4m

Compensación total

Porcentaje del salario del CEO	6.8%
Permanencia del CEO	1.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Hollingshead en comparación con los beneficios de Insulet?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$12m	US$842k	US$206m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$63m
Mar 31 2023	n/a	n/a	US$600k
Dec 31 2022	US$11m	US$440k	US$5m
Sep 30 2022	n/a	n/a	US$17m
Jun 30 2022	n/a	n/a	US$35m
Mar 31 2022	n/a	n/a	US$45m
Dec 31 2021	US$290k	n/a	US$17m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	US$9m
Dec 31 2020	US$259k	n/a	US$7m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	US$5m
Dec 31 2019	US$261k	n/a	US$12m

Compensación vs. Mercado: Jim($USD11.18M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD4.73M).

Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.

CEO

Jim Hollingshead (60 yo)

1.8yrs

Permanencia

US$12,379,765

Compensación

Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Hollingshead	President	1.8yrs	US$12.38m	0.020% $ 2.2m
Lauren Budden	Group VP	5yrs	US$1.44m	0.0081% $ 889.5k
Mark Field	Senior VP & CTO	less than a year	US$2.37m	0.013% $ 1.4m
John Kapples	Senior VP & General Counsel	5.1yrs	US$2.47m	0.021% $ 2.3m
Shacey Petrovic	Director & Advisor	1.8yrs	US$278.46k	0.045% $ 5.0m
Eric Benjamin	Executive VP	6.2yrs	US$3.14m	0.024% $ 2.6m
Prem Singh	Senior Vice President of Global Operations	1.3yrs	sin datos	0.0077% $ 842.5k
Deborah Gordon	Vice President of Investor Relations	9.3yrs	sin datos	sin datos
Laetitia Cousin	Senior VP of Regulatory Affairs	1.3yrs	sin datos	0.0044% $ 485.2k
Angela Wiczek	Senior Director of Corporate Communications	no data	sin datos	sin datos
Philip Hildale	Senior Vice President of Sales & Customer Care	9.3yrs	sin datos	sin datos
Andrew Isaacson	Senior VP of Strategy & Corporate Development	no data	sin datos	sin datos

1.8yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GOV no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Hollingshead	President	4.8yrs	US$12.38m	0.020% $ 2.2m
Shacey Petrovic	Director & Advisor	5.6yrs	US$278.46k	0.045% $ 5.0m
Elizabeth Weatherman	Independent Director	2.2yrs	US$322.50k	0.0023% $ 253.5k
Timothy Scannell	Independent Chairman	9.7yrs	US$387.10k	0.036% $ 4.0m
Robert Sherwin	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Howard Wolpert	Member of Scientific Advisory Board	no data	sin datos	sin datos
Margaret Lawlor	Member of Educator Advisory Board	no data	sin datos	sin datos
Camille Izlar	Member of Educator Advisory Board	no data	sin datos	sin datos
Mary Halvorson	Member of Educator Advisory Board	no data	sin datos	sin datos
Steven Edelman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anne Daly	Member of Educator Advisory Board	no data	sin datos	sin datos
Corinne Nevinny	Independent Director	5.3yrs	US$333.46k	0.0074% $ 806.5k

5.3yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de GOV se considera experimentada (4.9 años de antigüedad promedio).

Insulet Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Announces Board Changes

Director & Advisor recently sold €2.3m worth of stock

Insulet Corporation Announces CFO Transition

Insider recently bought €933k worth of stock

Recent updates

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: US$2.96 (vs US$0.066 in FY 2022)

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Now 20% undervalued

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Director & Advisor recently sold €2.3m worth of stock

Now 21% undervalued after recent price drop

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.74 (vs US$0.075 loss in 3Q 2022)

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

New minor risk - Share price stability

Insulet Corporation Announces CFO Transition

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.51 loss in 2Q 2022)

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Insider recently bought €933k worth of stock

Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation

First quarter 2023 earnings released: EPS: US$0.34 (vs US$0.40 in 1Q 2022)

Executive VP recently sold €367k worth of stock

Full year 2022 earnings released: EPS: US$0.066 (vs US$0.25 in FY 2021)

Insulet Corporation (NasdaqGS:PODD) acquired Assets of Automated Glucose Control LLC for $25 million.

Insulet Corporation to Report Q4, 2022 Results on Feb 23, 2023

Insulet Corporation Announces Executive Changes

Executive VP & Chief Commercial Officer recently sold €854k worth of stock

Insulet Corporation Announces Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System

Third quarter 2022 earnings released: US$0.075 loss per share (vs US$0.18 profit in 3Q 2021)

Insulet Corporation Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Insulet Corporation Provides Revenue Guidance for the Quarter Ending December 31, 2022

Insulet Corporation to Report Q3, 2022 Results on Nov 03, 2022

Executive VP & Chief Commercial Officer recently sold €768k worth of stock

Insulet Corporation Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Second quarter 2022 earnings released: US$0.51 loss per share (vs US$0.38 loss in 2Q 2021)

Insulet Corporation Provides Revenue Guidance for the Quarter Ending September 30, 2022 and Year Ending December 31, 2022

Insulet Corporation Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System

Insulet Corporation to Report Q2, 2022 Results on Aug 04, 2022

Executive VP & COO recently sold €1.2m worth of stock

Omnipod(R) 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

First quarter 2022 earnings released

Insulet Corporation Provides Revenue Guidance for the Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Insulet Corporation, Annual General Meeting, May 24, 2022

Insulet Corporation to Report Q1, 2022 Results on May 05, 2022

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2022 and Year Ending December 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Insulet Corporation Promotes Inclusivity for People with Diabetes Through Nintendo® Video Game Animal Crossing™: New Horizons

Insulet Corporation Announces Board Changes

Insulet Corporation Announces FDA Clearance of Its Omnipod 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control

Third quarter 2021 earnings released: EPS US$0.18 (vs US$0.18 in 3Q 2020)

Executive VP & Chief Commercial Officer recently sold €750k worth of stock

Executive VP & COO recently sold €1.0m worth of stock

Insulet Corporation Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States

Insulet Introduces Omnipod DASH System at Australasian Diabetes Congress

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.22 profit in 2Q 2020)

Insulet Corporation Announces Notice of Settlement of Derivative Suit

Insulet Corporation’S Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 Years

Insulet Corporation to Present New Clinical Data for Preschool Children and Adults Using the Omnipod 5 System

Executive VP & COO recently sold €409k worth of stock

Independent Director recently sold €179k worth of stock